# 1. Financial Performance ## A. Key Figures * **Total Income:** **₹67.5 Cr** H2 FY26 (+18.4%) · **₹137 Cr** FY26 (+34.6%) [Page 2 of 23] * **EBITDA:** **₹24.2 Cr** H2 FY26 · **₹58.8 Cr** FY26 (+49%) * **EBITDA Margin:** **42.9%** FY26 (+400 bps) ## B. Revenue & Profit * **Operational Headwinds:** H2 performance saw a temporary revenue dip due to a **1.5-month productivity loss** caused by an extended holiday break through late January. * **Cost-Efficiency Moat:** Management maintains a competitive advantage by positioning services at a significantly lower price point than major chains like **Apollo or Fortis**. * **Infrastructure Reinvestment:** H2 earnings were impacted by maintenance capex and upgrades to patient rooms and theaters at a **10-year-old** facility. * **Pre-operative Benchmarks:** Future scaling costs are projected at **₹1.25 Cr** for 50 beds, scaling to **₹3–3.5 Cr** for 200-bed facilities. ## C. Margin Performance * **Operating Leverage:** Robust margin expansion was driven by stagnant fixed and utility costs at mature facilities, alongside a superior service mix. * **Profit Sensitivity:** Management noted that **60% of revenue beyond breakeven** typically flows to profit, making the bottom line highly sensitive to high-margin revenue erosion. ## D. Balance Sheet & Receivables * **Receivable Normalization:** Efforts to restructure government payment schedules have already reduced receivable days from **320** to the **180–200** range, with a target of **150 days**. * **Liquidity Inflow:** Immediate cash flow relief is expected via an imminent **₹9–10 Cr** payment from the ministry, with a larger tranche due in **July**. * **Geographic Concentration:** While Uganda currently accounts for the vast majority of revenue, the balance sheet is expected to diversify as new projects stabilize over **4 to 6 quarters**. ## E. Cash Flow Dynamics * **Margin Compression Outlook:** A projected decline of **6% to 8%** in margins is anticipated due to rising depreciation from new equipment and increased finance costs. * **Capital Structure Shift:** The company is transitioning from a debt-free status in Uganda to utilizing bank funding to accelerate growth initiatives. --- # 2. Capacity & Infrastructure ## A. Bed Capacity Expansion * **Strategic Scaling:** Doubled overall capacity in FY26, focusing on a niche **50–200 bed** model to differentiate from larger competitors. * **Regional Market Dynamics:** African expansion is calibrated to local economics; Uganda is capped at **200–250 beds** due to paying capacity, while Kenya and Tanzania can support up to **500 beds** under national insurance schemes. * **Pune Pipeline:** Advancing a **125-bed greenfield facility** alongside a massive **750-bed** consultancy project (PHRC), which includes a private wing and a teaching hospital. ## B. Facility Commissioning Timelines * **Operational Milestones:** Navi Mumbai became fully operational in mid-February 2026 following ICU licensing; full commissioning of all services is targeted for **July 2026** with a **12-month** breakeven target. * **Project Velocity:** Brownfield sites and acquisitions are reaching financial milestones in roughly half the time of greenfield projects (**6 months** vs **12 months**). * **Long-term Horizon:** The large-scale PHRC project is slated for a five-year development cycle, with a projected go-live date in **2031 or 2032**. ## C. Asset-Light Model & Infrastructure * **Capital Efficiency:** Strategy avoids land/building ownership to minimize CAPEX while equipping standalone tertiary centers with high-end modular theaters, cath labs, and advanced diagnostics. * **Licensing & Equipment:** Final regulatory approvals for Navi Mumbai (FDA, CT, MRI) are expected by **late June 2026**, with heavy diagnostic equipment installation requiring a **2.5 to 3 week** lead time. --- # 3. Operating Segments & Geography ## A. Key Figures * **Consolidated Margin Floor:** **30%** * **Acquisition Capex:** **₹25 Cr - ₹30 Cr+** Brownfield (100-bed) · **₹15 Cr - ₹17 Cr** Greenfield (50-bed) ## B. India Market Entry * **Strategic Pivot:** Expanding into the domestic market to bypass African scalability caps, leveraging favorable local demographics and insurance tailwinds. * **Brand Positioning:** Management is deploying a multi-pronged strategy to bridge the brand recognition gap between Unihealth and established Tier-1 Indian hospital chains. * **New Capacity:** Recently functional sites in **Navi Mumbai and Nashik** are expected to improve receivable cycles and diversify revenue streams. ## C. East Africa Operations * **Uganda Volatility:** Significant H2 contraction attributed to a seasonal lean period for elective procedures and disruption from the **5-year national elections**. * **Geographic Focus:** Investment is strictly concentrated in **5 to 7 East African nations** to mitigate the diverse geopolitical risks present across the continent. * **Competitive Moat:** Maintains a "unique African angle" and operational bandwidth that differentiates the firm from larger Indian peers. ## D. Vertical Mix Performance * **Margin Stabilization:** High-margin consultancy and pharmaceutical distribution verticals act as a hedge, maintaining consolidated margins above the 30% threshold. * **Integrated Model:** Business remains diversified across hospital operations, consultancy, pharma exports, and medical value travel. ## E. M&A & Partnerships * **Tanzania Expansion:** Negotiations for a **100-bed tertiary care hospital** in Dar-es-Salaam are finalized; operational takeover and immediate revenue contribution expected by **Q3/Q4**. * **Contract Pipeline:** Management estimates a **51% probability** of securing the PHRC management contract, leveraging their involvement in the project since 2019. * **Inorganic Strategy:** Preference for brownfield acquisitions to secure established patient loads and faster profitability despite the higher upfront capital requirements. --- # 4. Patient & Clinical Metrics ## A. Key Figures * **Navi Mumbai ARPOB:** **₹32,000–₹35,000** Revised FY Target (Up from **₹27,500**) · **₹32,000–₹32,500** Initial Actuals * **Consolidated Targets:** **60%** Occupancy (~300 beds) · **₹27,500** ARPOB · **₹1 Cr** Annual Revenue Per Bed ## B. ARPOB & Occupancy * **Operational Outperformance:** Navi Mumbai is significantly exceeding initial ARPOB expectations, bolstering management confidence in accelerated breakeven timelines. * **Seasonal & Cyclical Tailwinds:** Following a lean period in early Q1, volumes are projected to surge through August driven by monsoon-related medical ICU cases and viral infections. * **Ramp-up Dynamics:** Occupancy typically scales from low single digits to double digits by month four, with a major inflection point expected upon completion of **corporate and insurance empanelments**. * **Efficiency Model:** The smaller hospital format is utilized to maintain superior patient-to-staff ratios, ensuring personalized care and optimized clinical protocols. ## C. Specialty Service Mix & Clinical Milestones * **Specialty Expansion:** Mature facilities are diversifying into high-value super specialties including neurosurgery, cardiology, and ophthalmology to sustain growth. * **Clinical Achievement:** Successfully recorded the **first IVF twin birth** at UMC Victoria Hospital, validating the group's enhanced specialty healthcare capabilities. ## D. International Patient Traffic * **Medical Value Travel (MVT):** Leveraging an established MVT vertical in the Middle East and Africa to funnel international patients into Indian facilities, with early success already noted in Navi Mumbai. * **Geographic Diversification:** Active patient inflows from Uganda and Tanzania are being supplemented by expansion into **Kenya and Nigeria**, with future entries into **Oman and Iraq** pending geopolitical stabilization. * **Inflow Outlook:** Management anticipates a significant contribution from international patients at both Navi Mumbai and Nashik by the end of the current fiscal year. --- # 5. Human Capital & Operations ## A. Key Figures * **Staffing Ratio:** **4 employees per bed** at full occupancy · **40% of total staff** hired pre-operatively * **Breakeven Threshold:** **50% occupancy** · **₹2 Cr monthly revenue** (for 50-bed unit) * **Incremental Margin:** **~60%** of revenue contributes to margin post-breakeven ## B. Doctor Recruitment Strategy * **Value Proposition:** Competes with tier-1 corporate hospitals by offering superior agility, advanced technology, and an **accelerated payment system** that settles dues daily or weekly. * **Targeted Talent Acquisition:** Focuses on skilled consultants in the **35–50 age bracket** seeking leadership roles and better commercial prospects than those available in stagnant senior-heavy corporate structures. * **Network-Led Growth:** Leverages over **20 years of management relationships** to onboard talent; the Navi Mumbai facility has already secured over **130 consultants** via peer-referral networks. * **Strategic Positioning:** Targets a "middle-ground" demographic requiring services priced below premium corporate rates but above government facilities, providing doctors with high-volume clinical opportunities. ## C. Manpower Cost Structure * **Operational Efficiency:** Maintains a lean administrative overhead compared to major peers, enabling flexible pricing for lower-income strata without eroding long-term profitability. * **Quality Assurance Investment:** Prioritizes high wages for specialized nursing and a **24/7 on-ground senior medical team** to ensure uncompromising post-operative care for critical cases. * **Pre-Commissioning Spend:** Initial staffing begins **3 to 6 months** post-conceptualization, with average consolidated expenditure per employee at **₹30,000**. ## D. Operational Breakeven Targets * **Accelerated Timeline:** Navi Mumbai is targeting operational breakeven by **September 30, 2026**, supported by higher-than-anticipated ARPOB and complex surgical volumes (cardiac/robotic). * **Ramp-up Velocity:** Facilities launch all departments concurrently; revenue typically reaches **30%–40%** of targets by month 6, with full financial breakeven aimed for months **9 to 12**. * **Operating Leverage:** Profitability is highly sensitive to breakeven speed; once reached, variable costs are capped at **30%**, allowing for potential margins in the **late 30s**. ## E. Training & Bench Strength * **Cross-Continental Synergy:** The Indian expansion serves as a training ground to build a **technical and nursing bench strength** intended for future deployment to support rapid growth in African markets. * **Clinical Depth:** Ensures consultant retention by providing a full-time core of department heads across critical specialties to manage execution from concept to commissioning. --- # 6. Risks & Healthcare Regulatory ## A. Key Figures * **Facility Capacity:** **20-bed** specialized secondary care facility in Mwanza, Tanzania * **Licensing Lead Time:** **3 to 4 weeks** expected for Tanzania license · **3 to 6 months** for post-license empanelments ## B. Licensing & Bureaucratic Delays * **Infrastructure Readiness:** Facilities in Mwanza and Nashik are structurally complete; however, operational commencement remains contingent on pending regulatory approvals. * **Equipment Bottlenecks:** Nashik facility delivery of **MRI, CT scan, and ultrasound** units is currently stalled awaiting mandatory **PC-PNDT approval** from municipal authorities. * **Administrative Friction:** Recent timelines were impacted by external administrative shutdowns, including the Tanzanian general election and a central government census in India. ## C. Geopolitical & Talent Risks * **Strategic Geographic Mix:** Maintaining a robust Indian presence serves as a stakeholder "comfort zone" and provides a stable base for an Indian listed entity. * **Human Capital Scarcity:** Africa operations face a critical shortage of **technical and management staff**; India is being utilized as the primary hub for HR development to mitigate this gap. ## D. Payment & Credit Risks * **Sovereign Payment Recovery:** Previous government payment delays linked to election cycles are expected to resolve within the first half of the current financial year. * **Uganda Macro Tailwinds:** Healthcare payment metrics are improving due to **foreign dollar inflows** from oil and infrastructure projects, as Western investors mandate better service payment standards. * **Revenue Onboarding:** Management anticipates a multi-month lag between licensing and securing key corporate empanelments with entities such as **Konkan Railways** and **Rashtriya Chemicals and Fertilizer**. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Targets:** **₹250 Cr – ₹300 Cr** FY annual target · **15% – 25%** long-term growth (on ₹132 Cr base) * **Bed Capacity:** **500 – 600** beds by FY-end · **1,000** beds by CY2028 · **3,000 – 5,000** beds long-term vision * **EBITDA Margin:** **32% – 33%** baseline · **Early-to-mid 30s** 2028 target · **30%** minimum threshold ## B. Revenue Growth Targets * **Near-Term Acceleration:** Anticipating robust quarterly growth of **30% to 40%** as new operations scale from a low baseline. * **Unit Economics:** Targeting high-efficiency output of **INR 1 Cr to 1.1 Cr** per bed annually by FY29, supported by optimized occupancy and ARPOB. * **Growth Levers:** Top-line expansion driven by organic growth in existing hubs, international patient inflow, and a shift toward high-value super-specialty services. ## C. Long-term Bed Vision * **Geographic Pivot:** Scaling to a group total of **5,000 beds** by leveraging India’s superior scalability, as individual African markets face concentration limits. * **FY27 Capacity Roadmap:** Targeting **600 beds** across a diversified footprint, including mature assets in Uganda, break-even facilities in Navi Mumbai, and new capacity in Nashik and Tanzania. * **Strategic Balance:** Phase 1 expansion aims for a balanced portfolio of **500-600 beds in India** (scalability) and **400-500 beds in Africa** (high returns). ## D. Margin Stability Forecast * **Margin Resilience:** Management expects to defend consolidated EBITDA margins in the early 30s despite the dilutive impact of adding **200-300 newly commissioned beds**. * **Profitability Mix:** Future margins supported by a tiered portfolio of mature assets, facilities at break-even (operating at **18% to 22%** margins), and new acquisitions. * **Expansion Headwinds:** PAT margins are projected to moderate from historical highs of **20%-35%** to a sustainable range during the aggressive capital deployment phase. ## E. Expansion Phase Projections * **Risk Mitigation:** Executing a five-year strategy to cap any single international market's revenue contribution at **33%**, reducing geographical concentration risk. * **Execution Timeline:** The next two quarters are identified as "critical" for finalizing Tanzania expansions and ramping up the Nashik facility. * **Phased Growth:** Immediate projections focus on Phase 1; the significant **PHRC project** capacity is categorized as Phase 2 and currently excluded from financial forecasts.